Document Detail


Clinical targeting of the TNF and TNFR superfamilies.
MedLine Citation:
PMID:  23334208     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Inhibitors of tumour necrosis factor (TNF) are among the most successful protein-based drugs (biologics) and have proven to be clinically efficacious at reducing inflammation associated with several autoimmune diseases. As a result, attention is focusing on the therapeutic potential of additional members of the TNF superfamily of structurally related cytokines. Many of these TNF-related cytokines or their cognate receptors are now in preclinical or clinical development as possible targets for modulating inflammatory diseases and cancer as well as other indications. This Review focuses on the biologics that are currently in clinical trials for immune-related diseases and other syndromes, discusses the successes and failures to date as well as the expanding therapeutic potential of modulating the activity of this superfamily of molecules.
Authors:
Michael Croft; Chris A Benedict; Carl F Ware
Related Documents :
23255578 - Aggravation of inflammatory response by costimulation with titanium particles and mecha...
23665018 - Ag490 inhibits nfatc1 expression and stat3 activation during rankl induced osteoclastog...
24333758 - Chronic inflammation and extra-nodal marginal-zone lymphomas of malt -type.
24047528 - Consequences of iron accumulation in microglia and its implications in neuropathologica...
22339218 - Current immunotherapy of multiple sclerosis and future challenges: relevance of immune-...
18722718 - Apoptosis and non-apoptotic deaths in cancer development and treatment response.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2013-01-21
Journal Detail:
Title:  Nature reviews. Drug discovery     Volume:  12     ISSN:  1474-1784     ISO Abbreviation:  Nat Rev Drug Discov     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-02-01     Completed Date:  2013-04-22     Revised Date:  2014-04-08    
Medline Journal Info:
Nlm Unique ID:  101124171     Medline TA:  Nat Rev Drug Discov     Country:  England    
Other Details:
Languages:  eng     Pagination:  147-68     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Clinical Trials as Topic
Humans
Inflammation / drug therapy*,  immunology*,  metabolism
Molecular Targeted Therapy / methods
Receptors, Tumor Necrosis Factor / immunology*,  metabolism
Tumor Necrosis Factors / antagonists & inhibitors*,  immunology*,  metabolism
Grant Support
ID/Acronym/Agency:
AI070535/AI/NIAID NIH HHS; AI089624/AI/NIAID NIH HHS; AI100905/AI/NIAID NIH HHS; AI101403/AI/NIAID NIH HHS; AI33068/AI/NIAID NIH HHS; AI48073/AI/NIAID NIH HHS; AI49453/AI/NIAID NIH HHS; CA164679/CA/NCI NIH HHS; CA91837/CA/NCI NIH HHS; R01 AI033068/AI/NIAID NIH HHS; R01 AI048073/AI/NIAID NIH HHS; R01 AI049453/AI/NIAID NIH HHS; R01 AI103021/AI/NIAID NIH HHS; R01 CA091837/CA/NCI NIH HHS; R21 AI100905/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Receptors, Tumor Necrosis Factor; 0/Tumor Necrosis Factors
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Targeting eosinophils in allergy, inflammation and beyond.
Next Document:  Reactive dispersive contaminant transport in coastal aquifers: Numerical simulation of a reactive He...